Genetic mechanisms underlying Duchenne muscular dystrophy point to potential treatments
Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...
Max Planck Society2d
Mechanism for treating muscle wasting discovered
Utrophin increase in muscle cells after transcriptional adaptation normalises cell function in Duchenne muscular dystrophy ...
The EMBO Journal11d
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked to Duchenne muscular dystrophy
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
Pharmabiz15h
Santhera announces agreement with German GKV-SV on reimbursement for Agamree to treat Duchenne muscular dystrophy
Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...
The American Journal of Managed Care7d
Ifetroban Improves Heart Function in DMD
There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...
Managed Healthcare Executive2d
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Cyprus Mail on MSN9d
TELETHON’s charity gala dinner in Paphos a radiant night of giving
In an evening of generosity and solidarity, the TELETHON charity gala dinner was held successfully on February 1, 2025.
Baylor College of Medicine17d
Muscular Dystrophy
The rate of progression of the muscular dystrophies depends on the type of dystrophy. While some progress slowly, others confine the patient to a wheelchair within a few years. Significant advances in ...
Wave Life Sciences begins Phase 1 obesity trial
CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...